

**MILTON KEYNES Clinical Commissioning Group  
Prescribing Group**

Janet Corbett (JC)  
Helen Chadwick (HC)  
Nikki Woodhall (NW)  
Nigel Fagan (NF)  
Edward Sivills (ES)  
Fatima Mohri (FM)  
Richard Simpson (RS)

Head of Prescribing & Medicines Management, CCG  
Clinical Director of Pharmacy, MKUHFT  
Senior Medicines Management Technician, CCG  
GP, Red House Surgery  
GP, CMK Medical Centre  
GP, Newport Pagnell Medical Centre  
GP, Parkside Medical Centre

Bhervi Patel (BP)  
Vacant  
CNWL Nurse Rep  
Zainab Master (ZM)  
  
Sharon Wilmore

Community Pharmacist  
Patient Representative/Healthwatch  
Non-Medical Prescriber / Nurse Rep (rotate)  
NHSE Pharmacist  
  
Minutes, MKCCG

c.c. Dupe Fagbenro (DF)  
Adam Staten (AS)

Formulary Pharmacist, MKUHFT  
Federation GP (for information)

**Minutes of the Prescribing Group Meeting held on  
Wednesday 6<sup>th</sup> March 2019**

|           | <b>Present</b>  | <b>Action</b> |
|-----------|---|---------------|
|           | <p>Janet Corbett                      Nadia Emmony                      Edward Sivills<br/>Nikki Woodhall                      Richard Simpson                      Zainab Master<br/>Nigel Fagan                              Sharon Wilmore<br/>Bhervi Patel                              Dr Nikki Ramskill (attended)</p>  |               |
| <b>1.</b> | <b>Welcome, apologies and introductions</b>   |               |
|           | <ul style="list-style-type: none"> <li>• Apologies were received from: Helen Chadwick, Fatima Mohri and Lorraine Gardner (CNWL representative)</li> <li>• Zainab Master (replacing Aarti Shah) was welcomed to the group. Zainab is the NHSE pharmacist at three practices: Parkside, Westfield Road and Whaddon. Aarti was acknowledged and thanked for her input over the past year.</li> <li>• Geena Kirpalani has resigned from the group as her travelling and work commitments have changed. Geena was acknowledged and thanked for her input over the past couple of years.</li> <li>• Nadia has also resigned from the group as she is relocating. Nadia was thanked for her support and input over the many years she has been part of the group. Nadia will ask for a colleague to be nominated from Healthwatch to replace her.</li> <li>• Nikki Ramskill is a ST3 trainee GP (with RS) - guest</li> </ul> |               |
| <b>2.</b> | <b>Acknowledgement of declaration of any other business</b>   |               |
|           | None  |               |
| <b>3.</b> | <b>Notes of previous meeting</b>  |               |
|           | The minutes from 9 <sup>th</sup> January 2019 were signed by NF as an accurate record of the meeting.   |               |
| <b>4.</b> | <b>Matters Arising from previous meeting</b>  |               |
|           | <p><b>4.1 Edoxaban Update(Comms)</b><br/>The revised DOAC guidance was approved at MKPAG at the end of January. This has now been circulated to practices and Optimise messages are being developed.<br/>There were concerns about effective communication of guidance / information and MHRA safety alerts. At a recent meeting it was apparent that the GPs had not seen the email or the insert in Prescribing News (February edition).</p>  |               |

|                  |   |   |
|------------------|---|---|
|                  | <p>It was suggested that an email distribution list be created for the Prescribing Leads at each practice. An email to be sent to Practice Managers asking for names of the lead for prescribing. The Red Whale publication was mentioned by NF which is read by GPs – a recent article on DOACs and some safety concerns. NF will send JC a copy.</p> <p>The guidance has been added to the Formulary and will be attached to Optimise Rx messages. It was recommended that this guidance be put under the Guideline folder in the Formulary – NW to check and link.</p> <p><b>Item now closed</b></p>   | <p><b>SW/NW</b></p> <p><b>NF</b></p> <p><b>NW</b></p> |
|                  | <p><b>4.2 COPD Guidance</b></p> <p>NW has developed an updated COPD prescribing guidance in line with NICE. This recommends identifying those patients with and those without asthma features. An updated version was circulated to the group for comment after the Respiratory Leads wished to push away from Triple Therapy for patients with no asthma symptoms. A couple of amendments from ES and NF were suggested and these will be incorporated into another version. This guidance will now be taken to MKPAG.</p> <p>MKCCG has recently commissioned a new respiratory diagnostic hub called AIRS (Assessment &amp; Investigation of Respiratory Symptoms) a diagnostic one stop service for patients This will work alongside established Respiratory PCOC – referrals into AIRS will be screened and passed on to PCOC if appropriate. Whaddon Surgery and Brooklands are hosting clinics for AIRS.</p>   |   |
| <p><b>5.</b></p> | <p><b>Eclipse RADAR update</b></p>  |   |
|                  | <ul style="list-style-type: none"> <li>• New staff have been taken on at Eclipse and MK now have a regional account manager and trainer – Terry Rugg. He is visiting practices to ensure they are getting the most from Eclipse (including setting up Little GEM – easier for practices to identify patients and the separate Diabetes module)</li> <li>• Still ongoing IT problems with Watling Vale and Brooklands.</li> <li>• £3 per head scheme – likely to continue until April 2019 and currently investigating opportunities to pay practices for using RADAR in 19/20 (look at red and a proportion of Amber alerts)</li> <li>• National funding for Eclipse RADAR is available to us until March 20. The company are currently trying to increase this further.</li> <li>• Learning Disabilities element is being looked at as this is a priority area for the CCG this year.</li> <li>• More information will follow in due course.</li> </ul> <p>The group continue to support the use of Eclipse RADAR and feel it is a useful patient safety tool.</p> |   |
| <p><b>6.</b></p> | <p><b>Prescribing Incentive Scheme 2019-20 (Final Draft)</b></p>  |   |
|                  | <ul style="list-style-type: none"> <li>• The Antibiotics Quality Premium has not been updated for 19/20, so we have continued in line with last year.</li> <li>• Trimethoprim for the over 70s – there are different baselines to recognise those practices that have already reduced significantly this year.</li> </ul>   |   |



|            |   |  |
|------------|---|--|
|            | <p>edition) to use 2.5mg tablets wherever possible and to discuss the risks of using two strengths with patients. JC has asked the hospital to feedback that when Consultants write to GPs that they need to be more directive in their instructions e.g. 4 x 2.5mg tablets (10mg).</p> <p>New high strength insulins are being added to the formulary as Amber 3 due to patient safety concerns (now 200 and 300 units / ml available). Applications have to be supported by a form developed by RMOC (Regional Medicines Optimisation Committees) to help mitigate these risks. Specialists should initiate and train / counsel the patients on the new doses before asking GPs to continue prescribing. A3 alert on Optimise will also help highlight the different strengths to prevent errors.</p> <p>Medical Director joined the meeting and the process of MKPAG was discussed. It was agreed that there should be more clinical engagement from the hospital consultants to progress agenda items in a more timely manner.</p> <p>Dupe Fagbenro will be leaving the hospital at the end of April. Dupe was acknowledged for her supportive role and will be missed.</p> |  |
| <b>10.</b> | <b>Future Agenda items</b>  |  |
|            | <p>RS mentioned indicative prescribing item from previous meeting. He is still looking at and will want to bring back to discuss at future meeting. JC confirmed that Emma Hooton had done some work on S1 formulary to support this.</p>   |  |
| <b>11.</b> | <b>AOB</b>  |  |
|            | <p>BP mentioned that if a script has 1 ON on it when sent via EPC then it will come out on label as this and not One at Night. NW said that she would ask EH that MK S1 formulary did not have any abbreviations on.</p> <p>Also a quick discussion was had about Controlled Drugs via EPS going live in MK on 7<sup>th</sup> March with not much information sent out to support this and no national feedback from pilot sites.</p>   |  |
| <b>12.</b> | <b>Date of Next Meeting</b>   |  |
|            | <p>The May 2019 meeting has been cancelled.</p> <p><b>Wednesday 3<sup>rd</sup> July 2019 7.30am</b><br/>Venue: Boardroom 1, Sherwood Place, Bletchley</p>   |  |

Minutes approved as an accurate record by:

(Signature): ..... Print Name: .....

Position: ..... Date: .....